Advertisement
News
Advertisement

Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration

Mon, 11/12/2012 - 3:14am

Foundation Medicine, Inc. announced today a multi-year collaboration with AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. Working with Foundation Medicine to reveal these genomic alterations may help AstraZeneca to research new medicines for people with cancer. Under the terms of the collaboration, Foundation Medicine was also granted right of first negotiation for the development of potential diagnostic products.

Susan Galbraith, Vice President and Head of the AstraZeneca Oncology Innovative Medicines Unit said, “Our scientific understanding of cancer and the pathways driving tumour growth enables us to focus on which people are most likely to respond to our medicines. This collaboration with Foundation Medicine will help us to identify tumour-specific defects and alterations that can be used for patient segmentation.”

“AstraZeneca has a strong commitment to understanding the patient-to-patient variations that may impact the efficacy of therapeutic candidates,” said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. “We are helping companies like AstraZeneca achieve deeper insight into their programs and trials with our unique cancer expertise and our ability to provide genomic information that can impact clinical treatment decisions. Together, we expect to enable a more individualized, targeted approach to cancer drug development and clinical trials.”

 

 

Advertisement
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading